BET DEGRADER

The present invention provides a BET (protein) degrader, specifically a BET degrader containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof: wherein L1 and L2 are the same or different and each represents a small molecular ligand for BET protein, and S represents a group represented by a formula selected from the group consisting of formulas (SI) to (S18).

COMPOUND WITH ANTICANCER ACTIVITY

A compound with anticancer activity or a pharmaceutically permissible salt thereof is provided. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof is used. (In the formula, L1 andL2 are the same or different and represent a group represented by one formula selected from formulas (A) to (F), and S represents a group represented by one formula selected from formulas (S1) to (S18).

BET DEGRADER

Provided is a BET degrader. A BET degrader including a compound represented by formula (I) or a pharmaceutically acceptable salt thereof is used. (In the formula, L1 and L2 are the same or different and represent a low molecular ligand for a BET protein, and S represents a group represented by one formula selected from the group consisting of formulas (S1)-(S18).) ...

COMPOUND WITH ANTICANCER ACTIVITY

A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: (wherein, L1 and L2 are the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).

COMPOUND WITH ANTICANCER ACTIVITY

COMPOUND WITH ANTICANCER ACTIVITY

A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: 2. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Lis a member selected from formula (A) claim 1 , (B) claim 1 , (C) claim 1 , (D) claim 1 , or (F) claim 1 , Lis a member selected from formula (A) claim 1 , (B) claim 1 , (C) claim 1 , or (D) claim 1 , and S is a member selected from formula (S1).3. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Land Lare independently a member selected from formula (A) claim 1 , and S is a member selected from formula (S2).4. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Lrepresents a member selected from formula (A) claim 1 , (B) claim 1 , or (C) claim 1 , Lis a member selected from formula (A) or (B) claim 1 , and S is a member selected from formula (S3).5. The compound according to or a pharmaceutically acceptable salt thereof claim 1 , wherein Land Lindependently represent a member selected from formula (A) claim 1 , and S is a member selected from formula (S4) or (S5).6. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Lis a group member selected from formula (A) claim 1 , (B) claim 1 , (C) claim 1 , or (D) claim 1 , Lis a member selected from formula (A) claim 1 , (B) claim 1 , or (D) claim 1 , and S is a member selected from formula (S6).7. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Lis a member selected from formula (A) or (B) claim 1 , Lis a member selected from formula (A) claim 1 , and S is a member selected from formula (S7).8. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Lis a member selected from formula (A) or (B) claim 1 , Lis a member selected from formula (A) claim 1 , and S is a member-selected from formula (S8).9 ...

Nucleic acid suppressing expression of apcs

The present invention provides a double-stranded nucleic acid consisting of a sense-strand nucleic acid and an antisense-strand nucleic acid and comprising a double-strand region having at least 11 base pairs, for suppressing expression of APCS gene, in which an oligonucleotide chain having a chain length of at least 17 nucleotides and at most 30 nucleotides in the antisense-strand nucleic acid is complementary to a target APCS mRNA sequence comprising a base sequence set forth in any one of SEQ ID NOS: 1288 to 1930.

Nucleic acid suppressing expression of apcs

The present invention provides a double-stranded nucleic acid consisting of a sense-strand nucleic acid and an antisense-strand nucleic acid and comprising a double-strand region having at least 11 base pairs, for suppressing expression of APCS gene, in which an oligonucleotide chain having a chain length of at least 17 nucleotides and at most 30 nucleotides in the antisense-strand nucleic acid is complementary to a target APCS mRNA sequence comprising a base sequence set forth in any one of SEQ ID NOS: 1288 to 1930.

Compound with anticancer activity

A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:(wherein, L1 and L2 are the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).

System management method, system management device, system management program, and storage medium containing system management program

A system management method correlates a processing object and a processing to each node in the tree structure and operates each node according to the tree structure, thereby managing the processing object and the processing. A user who performs operation is registered in a general node corresponding to the processing object or a function node corresponding to the processing. The function node is set as a child node of the general node corresponding to the processing object to execute the processing corresponding to the function node while the general node is set as a parent node of the function node. A registered user operation authority is set for each of the registered users. When the registered user requests execution of the processing corresponding to the function node, the function node is caused to execute the processing only if the processing is permitted by the registered user operation authority of the registered user who has requested the processing set in the general node as a parent node of the function node.

Bet degrader

抗がん活性を有する化合物

【課題】本発明は、抗がん活性を有する化合物またはその薬学的に許容される塩を提供することを課題とする。【解決手段】本発明は、下記式(I)で表される化合物またはその薬学的に許容される塩を提供する：【化１】TIFF2024019395000136.tif21170(式中、L1およびL2は、それぞれ同一または異なって、式(A)-2で表される基を表し、Sは、式(S1)-1で表される基を表す)。【選択図】なし

Compound with anticancer activity

Compound with anticancer activity

A compound with anticancer activity or a pharmaceutically permissible salt thereof is provided. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof is used. (In the formula, L

Yhdiste, jolla on syöpää ehkäisevä vaikutus

Forbindelse med anticanceraktivitet

Compound with anticancer activity

A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:(wherein, L1 and L2 are the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).

Jedinјenјe sa antikancerogenom aktivnošću

Związek posiadający aktywność przeciwnowotworową

Spojina s protirakavim delovanjem

Compuesto con actividad antineoplásica

Se proporciona un compuesto con actividad anticancerígena o una sal farmacéuticamente aceptable del mismo. Se utiliza un compuesto representado por la fórmula (I) o una sal farmacéuticamente aceptable del mismo. (En la fórmula, L1 y L2 son iguales o diferentes y representan un grupo representado por una fórmula seleccionada entre las fórmulas (A) a (F), y S representa un grupo representado por una fórmula seleccionada entre las fórmulas (S1) a (S18). (Traducción automática con Google Translate, sin valor legal)

Compound with anticancer activity

A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:(wherein, L1 and L2 are the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).

Spoj s protutumorskom aktivnošću